SEC Filing Summary: Athira Pharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Athira Pharma, Inc. (not Leonabio, Inc.) on November 9, 2023. The filing serves as a current report to announce the issuance of a press release detailing financial results for the quarter ended September 30, 2023. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol ATHA.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. It references a press release (Exhibit 99.1) as the source for these figures but does not reproduce the data within the body of this 8-K document.
Material Changes
No specific material changes in financial condition or operations are detailed in this text. The filing solely notifies investors of the availability of the Q3 2023 results via the attached press release.
Guidance, Outlook, and Risks
The filing includes a Regulation FD disclosure (Item 7.01) outlining the company's communication channels. Athira Pharma states it uses SEC filings, press releases, conference calls, its website, and social media platforms (X, LinkedIn, Instagram, Facebook) to disseminate material information. No specific forward-looking guidance, risk factors, or unusual items are described in this excerpt.
Investor Verification Checklist
- Verify the correct registrant name is Athira Pharma, Inc., as the input metadata incorrectly listed "Leonabio, Inc."
- Review Exhibit 99.1 (the press release) to obtain actual financial figures for the quarter ended September 30, 2023.
- Confirm the company's status as an Emerging Growth Company as indicated by the checkmark in the filing.
- Monitor the company's official social media channels for additional material disclosures as per Item 7.01.